[go: up one dir, main page]

WO2002018584A3 - Gene xage-1, exprime dans de nombreux cancers, et son utilisation - Google Patents

Gene xage-1, exprime dans de nombreux cancers, et son utilisation Download PDF

Info

Publication number
WO2002018584A3
WO2002018584A3 PCT/US2001/027258 US0127258W WO0218584A3 WO 2002018584 A3 WO2002018584 A3 WO 2002018584A3 US 0127258 W US0127258 W US 0127258W WO 0218584 A3 WO0218584 A3 WO 0218584A3
Authority
WO
WIPO (PCT)
Prior art keywords
proteins
xage
cancer
provides
analogs
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2001/027258
Other languages
English (en)
Other versions
WO2002018584A2 (fr
Inventor
Ira H Pastan
Xiu Fen Liu
Tapan K Bera
Byungkook Lee
Kristi A Egland
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
US Department of Health and Human Services
Original Assignee
US Department of Health and Human Services
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by US Department of Health and Human Services filed Critical US Department of Health and Human Services
Priority to US10/363,233 priority Critical patent/US20040087772A1/en
Priority to AU2001287004A priority patent/AU2001287004A1/en
Publication of WO2002018584A2 publication Critical patent/WO2002018584A2/fr
Publication of WO2002018584A3 publication Critical patent/WO2002018584A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Cette invention concerne la découverte inattendue que XAGE-1 est traduit en deux protéines, une protéine de 9 kD appelée p9 et une protéine de 16,3 kD appelée p16. Elle concerne également la découverte inattendue que XAGE-1 est exprimé dans un grand nombre de cancers humains, notamment le cancer de la prostate, le cancer du poumon, le cancer de l'ovaire, le cancer du sein, le glioblastome, le cancer du pancréas, le lymphome T, le mélanome, et le lymphome histiocytaire. Les protéines p9 et p16, leurs fragments immunogènes, leurs analogues, et des acides nucléiques codant ces protéines, fragments ou analogues, peuvent être administrés à des personnes atteintes d'un cancer exprimant XAGE-1, aux fins d'élever ou d'augmenter une réponse immunitaire contre ce cancer. L'invention concerne également des séquences d'acide nucléique codant les protéines de l'invention, ainsi que des vecteurs d'expression, des cellules hôtes, et des anticorps inhibant ces protéines. Elle concerne aussi des immunoconjugués qui comprennent un anticorps inhibant des protéines p16 et p9, et une molécule effectrice, telle qu'un marqueur, un radioisotope ou une toxine. L'invention concerne en outre des méthodes qui permettent d'inhiber la croissance de cellules exprimant XAGE-1 en plaçant celles-ci au contact d'immunoconjugués comprenant un anticorps anti- p9 ou p16 et un fragment toxique. L'invention concerne enfin des nécessaires qui permettent de détecter la présence de p9 ou p16 dans un prélèvement.
PCT/US2001/027258 2000-09-01 2001-08-31 Gene xage-1, exprime dans de nombreux cancers, et son utilisation Ceased WO2002018584A2 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US10/363,233 US20040087772A1 (en) 2001-08-31 2001-08-31 Xage-1, a gene expressed in multiple cancers, and uses thereof
AU2001287004A AU2001287004A1 (en) 2000-09-01 2001-08-31 Xage-1, a gene expressed in multiple cancers, and uses thereof

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US22968400P 2000-09-01 2000-09-01
US60/229,684 2000-09-01

Publications (2)

Publication Number Publication Date
WO2002018584A2 WO2002018584A2 (fr) 2002-03-07
WO2002018584A3 true WO2002018584A3 (fr) 2003-01-16

Family

ID=22862271

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/027258 Ceased WO2002018584A2 (fr) 2000-09-01 2001-08-31 Gene xage-1, exprime dans de nombreux cancers, et son utilisation

Country Status (2)

Country Link
AU (1) AU2001287004A1 (fr)
WO (1) WO2002018584A2 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004092213A1 (fr) 2003-04-08 2004-10-28 The Government Of The United States Of America As Represented By The Secretary, Department Of Healthand Human Services Gene exprime dans le cancer de la prostate, procedes et utilisation correspondants
US20130171178A1 (en) * 2003-12-12 2013-07-04 The Government Of The United States As Represented By The Secretary Of Health And Human Services Immunogenic Peptides of Xage-1
CN103293308B (zh) * 2013-05-24 2014-11-26 尉军 一种检测肿瘤标志物p16抗原表位氨基酸序列及应用
EP3535288A1 (fr) 2016-11-07 2019-09-11 Immunocore Limited Peptides

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001000828A2 (fr) * 1999-06-30 2001-01-04 Corixa Corporation Compositions et techniques de therapie et de diagnostic du cancer du poumon
WO2001042451A2 (fr) * 1999-12-08 2001-06-14 Genset ADNc HUMAINS PLEINE LONGUEUR CODANT POUR DES PROTEINES POTENTIELLEMENT SECRETEES
EP1179589A1 (fr) * 2000-08-08 2002-02-13 F. Hoffmann-La Roche Ag MMX-1, mémbre de la famille d'antigènes Tumeur/Testicules et méthode pour éssayer la capacité métastatique d'un tumeur

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001000828A2 (fr) * 1999-06-30 2001-01-04 Corixa Corporation Compositions et techniques de therapie et de diagnostic du cancer du poumon
WO2001042451A2 (fr) * 1999-12-08 2001-06-14 Genset ADNc HUMAINS PLEINE LONGUEUR CODANT POUR DES PROTEINES POTENTIELLEMENT SECRETEES
EP1179589A1 (fr) * 2000-08-08 2002-02-13 F. Hoffmann-La Roche Ag MMX-1, mémbre de la famille d'antigènes Tumeur/Testicules et méthode pour éssayer la capacité métastatique d'un tumeur

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
BRINKMANN U ET AL: "Novel genes in the PAGE and GAGE family of tumor antigens found by homology walking in the dbEST database", CANCER RESEARCH, AMERICAN ASSOCIATION FOR CANCER RESEARCH, BALTIMORE, MD, US, vol. 59, no. 7, 1 April 1999 (1999-04-01), pages 1445 - 1448, XP002177257, ISSN: 0008-5472 *
DATABASE EMBL [online] 23 August 2000 (2000-08-23), LIU X ET AL: "Homo sapiens XAGE-1 mRNA, complete cds.", XP002210234, retrieved from EBI Database accession no. AF251237 *
LIU XIU FEN ET AL: "XAGE-1, a new gene that is frequently expressed in Ewing's sarcoma.", CANCER RESEARCH, vol. 60, no. 17, 1 September 2000 (2000-09-01), pages 4752 - 4755, XP002210232, ISSN: 0008-5472 *
ZENDMAN ALBERT J W ET AL: "Characterization of XAGE-1b, a short major transcript of cancer/testis-associated gene XAGE-1, induced in melanoma metastasis.", INTERNATIONAL JOURNAL OF CANCER, vol. 97, no. 2, January 2002 (2002-01-01), pages 195 - 204, XP002210233, ISSN: 0020-7136 *

Also Published As

Publication number Publication date
AU2001287004A1 (en) 2002-03-13
WO2002018584A2 (fr) 2002-03-07

Similar Documents

Publication Publication Date Title
WO2001053349A3 (fr) Antigenes associes au cancer du poumon a petites cellules et utilisations de ces antigenes
Seymour et al. A processed multidomain Mycoplasma hyopneumoniae adhesin binds fibronectin, plasminogen, and swine respiratory cilia
WO2000073801A3 (fr) Antigenes associes au cancer du sein, de la prostate et de l'estomac et leur utilisation
NZ783695A (en) Binding molecule specific for cd73 and use of binding molecule
NO20021992L (no) Anti-prostatastamcelleantigen(PSCA)-antistoffpreparat og fremgangsmåter for anvendelse
WO2004024750A3 (fr) Ligands liant cd44
WO2003092630A3 (fr) Identification d'anticorps monoclonaux humains largement neutralisants a reaction croisee au moyen d'un procede d'adherence sequentielle sur plaque d'antigenes de banques de presentation du phage
WO2007067730A3 (fr) Anticorps monoclonaux humains contre la proteine tyrosine kinase 7 (ptk7) et procedes pour utiliser des anticorps anti-ptk7
NZ331866A (en) Compounds for immunotherapy and immunodiagnosis of prostate cancer
BRPI0516264A (pt) molécula de ácido nucleico, seqüência de nucleotìdeos, cassete de expressão, vetor de expressão, célula, métodos para expressar um anticorpo recombinante ou fragmento do mesmo, para melhorar a expressão de um anticorpo recombinante ou fragmento do mesmo, para produzir um anticorpo recombinante ou fragmento do mesmo e uma preparação de anticorpos e para detectar um produto irt em uma amostra, anticorpo e composição farmacêutica
NZ595896A (en) Genetic products differentially expressed in tumors and the use thereof
EP1633784A4 (fr) Compositions d'anticorps anti-ovr110, et leur procede d'utilisation
WO2002092836A3 (fr) Sequence nucleotidique codant un antigene ovarien ca125 et ses utilisations
WO2000020587A3 (fr) Antigenes associes au cancer et leurs utilisations
WO2005097185A3 (fr) Anticorps irta-5 et utilisations de ces derniers
CN105277712B (zh) 一种鉴定赖氨酸ε‑氨基侧链单甲基化修饰的方法
AU3217100A (en) Methods of use of a novel lysyl oxidase-related protein
WO2003033520A3 (fr) Vaccin anticancereux, methodes diagnostiques et reactifs
AU2003287115A1 (en) Fluorescent proteins from copepoda species and methods for using same
WO2004067564B1 (fr) Compositions contre l'antgene cancereux liv-1 et leurs utilisations
WO2002018584A3 (fr) Gene xage-1, exprime dans de nombreux cancers, et son utilisation
Chen et al. Neoglycoproteins: preparation and properties of complexes of biotinylated asparagine-oligosaccharides with avidin and streptavidin
Andoh et al. Disulfide bridges in proteins linking DNA in cultured mouse fibroblasts, strain L· P3
Host et al. Enzymatic methylation of the Mycobacterium tuberculosis heparin-binding haemagglutinin
WO1999029724A3 (fr) ADN CODANT UNE PROTEINE MEMBRANAIRE EXTERIEURE DE $i(PASTEURELLA MULTOCIDA)

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PH PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 10363233

Country of ref document: US

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP